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USP9X deubiquitylating enzyme 
maintains RAPTOR protein 
levels, mTORC1 signalling and 
proliferation in neural progenitors
Caitlin R. Bridges1, Men-Chee Tan1, Susitha Premarathne1, Devathri Nanayakkara1, 
Bernadette Bellette1, Dusan Zencak1, Deepti Domingo2, Jozef Gecz  2,3, Mariyam Murtaza1, 
Lachlan A. Jolly3 & Stephen A. Wood  1
USP9X, is highly expressed in neural progenitors and, essential for neural development in mice. In 
humans, mutations in USP9X are associated with neurodevelopmental disorders. To understand 
USP9X’s role in neural progenitors, we studied the effects of altering its expression in both the 
human neural progenitor cell line, ReNcell VM, as well as neural stem and progenitor cells derived 
from Nestin-cre conditionally deleted Usp9x mice. Decreasing USP9X resulted in ReNcell VM cells 
arresting in G0 cell cycle phase, with a concomitant decrease in mTORC1 signalling, a major regulator 
of G0/G1 cell cycle progression. Decreased mTORC1 signalling was also observed in Usp9x-null 
neurospheres and embryonic mouse brains. Further analyses revealed, (i) the canonical mTORC1 
protein, RAPTOR, physically associates with Usp9x in embryonic brains, (ii) RAPTOR protein level is 
directly proportional to USP9X, in both loss- and gain-of-function experiments in cultured cells and, (iii) 
USP9X deubiquitlyating activity opposes the proteasomal degradation of RAPTOR. EdU incorporation 
assays confirmed Usp9x maintains the proliferation of neural progenitors similar to Raptor-null and 
rapamycin-treated neurospheres. Interestingly, loss of Usp9x increased the number of sphere-forming 
cells consistent with enhanced neural stem cell self-renewal. To our knowledge, USP9X is the first 
deubiquitylating enzyme shown to stabilize RAPTOR.
The proliferation, self-renewal and differentiation of neural stem cells (NSCs), and their closely related deriv-
atives, neural progenitors (NPs), in both the developing and adult nervous systems, are tightly controlled by 
both extrinsic and intrinsic signals. Extrinsic signals, derived from the stem cell niche or embryonic organising 
centres, need to be recognised, relayed internally, coordinated and interpreted to ultimately produce a precise 
cellular response. Cell polarity, adhesion, cycle length and migration all influence the response to extrinsic sig-
nals. Concerning the cell cycle, the G0 and G1 phases are particularly involved in dictating the fate of a NP1. 
Specifically, it is the length of the G1 phase that regulates progenitor differentiation. Cells that linger in these 
phases have increased longevity and retain the capacity to self-renew1. Multiple extrinsic signals influence NP 
cell cycle progression and the intracellular mammalian target of rapamycin (mTOR) pathway responds to many 
of these growth factors by coordinating an appropriate RNA and protein synthesis response and, as such, is a 
major regulator of G0/G1 cell cycle progression. mTOR is an ubiquitous protein kinase found in two complexes, 
mTORC1 and mTORC2. The mTORC1 complex, which consists of mTOR, regulatory-associated protein of 
mTOR (RAPTOR) and mammalian lethal with SEC13 protein 8 (MLST8), responds to growth factor stimulation 
and links this, along with nutrient availability, to cell growth and division2, 3. In particular, mTORC1 response to 
growth factor stimulation is required for cell cycle progression through the G1 phase of the cell cycle2.
mTOR is a critical regulator of NSC/NP function in vivo and in vitro balancing self-renewal, proliferation, 
differentiation and maturation4. Dysregulation of mTOR signalling gives rise to neurodevelopmental disorders5, 6. 
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Hyperactivation of the mTOR pathway, due to loss of function mutations in the TSC1 and TSC2 genes, upstream 
inhibitors of mTOR, gives rise to Tuberous Sclerosis Complex (TSC). TSC is characterized by benign malforma-
tions comprised of aberrantly proliferating non-malignant cells of the tissue of origin. In the brain, these lesions 
are ectopic neurogenic compartments with enhanced proliferation of NPs and their subsequent premature differ-
entiation7. Conversely loss of mTORC1 function results in decreased NP proliferation. Deletion of RAPTOR, an 
essential protein of the mTORC1 complex, from NPs of the dorsal telencephalon leads to decreased proliferation 
but not loss of self-renewal capacity8. Similarly, these cardinal features are seen in ex-vivo cultures of murine NSC/
NPs grown as free-floating aggregates, called neurospheres, lacking mTORC1 function: inhibition of mTORC1 
signalling in neurospheres, by addition of rapamycin, also decreased proliferation of NPs without affecting the 
self-renewing capacity of the NSCs9. Therefore, mTOR signalling needs to be tightly balanced to maintain home-
ostasis in NPs.
Another protein well placed to integrate extrinsic signals with the intrinsic responses of NPs, is the 
ubiquitin-specific protease 9 located on the X-chromosome (USP9X). USP9X is a deubiquitylating enzyme 
highly expressed in adult and embryonic NPs in vivo, and in vitro10. Altering Usp9x expression levels affects NP 
function. Moderately increased Usp9x expression in mouse embryonic stem cell-derived NPs in vitro promotes 
their self-renewal leading to a large increase in the number of NPs11. Conversely, Nestin-cre mediated deletion 
of Usp9x from all NPs of the mouse central nervous system disrupted their organisation in the ventricular and 
sub-ventricular zones and results in peri-natal lethality12. Deletion of Usp9x from the dorsal telencephalon only, 
is compatible with post-natal survival, but results in a dramatic 75% reduction in adult hippocampal size, suggest-
ing NP proliferation is reduced12. Mutations in human USP9X are associated with several neurodevelopmental 
disorders including X-linked intellectual disability and autism13. In addition, mutations in Doublecortin that 
specifically disrupt its ability to interaction with USP9X, result in lissencephaly and severe epilepsy, further high-
lighting the importance of USP9X function for normal brain development14.
Recently, Usp9x has been implicated in mTOR signalling in C2C12 mouse muscle myoblasts15. Knockdown of 
Usp9x in these cells increased mTORC1 activity15. Epitope pull-down assays showed that Usp9x associated with 
mTOR, as well as RAPTOR and RICTOR, signature proteins of the mTORC1 and mTORC2 signalling complexes, 
respectively15. However altered expression of USP9X did not affect the level of mTOR protein in HEK293 cells. 
Here, we show that USP9X is a potent regulator of the mTORC1 signalling in NP/NSCs. Decreasing USP9X levels 
resulted in a rapid arrest of cultured NPs in G0/G1 of the cell cycle. Further we show that USP9X binds RAPTOR 
in the developing brain and maintains RAPTOR levels in cultured NPs suggesting RAPTOR is a critical USP9X 
substrate.
Results
USP9X depletion results in reduced neural progenitor number. To directly test the role, if any, of 
USP9X in NPs we altered its levels in the immortalized human NP cell line, ReNcell VM. To deplete USP9X 
in these cells, lentiviral vectors with doxycycline-inducible expression of shRNAs directed against USP9X were 
generated16. The lentiviral vector also expressed EGFP, which was used to identify and FACS purify, successfully 
transduced pools of cells, for subsequent experiments. Two independent shRNAs (2193 and 4774, indicating the 
position of the first base pair of the shRNA in the USP9X open reading frame) efficiently depleted USP9X and 
these cell lines were chosen for future experiments. Induction of a scrambled shRNA, as well as the addition of 
doxycycline, had no effect on USP9X protein levels (Fig. 1A). Partial loss of USP9X was evident 24 hours after 
doxycycline addition in 2193 and 4774 cells, and reached maximal levels by 72 hours (Fig. 1A). To examine the 
effect of USP9X depletion on ReNcell VM and determine the time of maximum effect, cells were analyzed using 
the xCELLigence system, which measures electrical impedance, and so is proportional to cell number, in real 
time. Analysis of two biological replicates revealed that the cell index of ReNcell VM cells expressing USP9X shR-
NAs plateaued approximately 20 hours after doxycycline addition (Fig. 1B). In 2193 and 4774 cells the decrease 
in cell index reached statistical significance (p < 0.05; analysis was obtained by plotting t-values of the two way 
ANOVA analysis versus time) at 34 hours and 28 hours, respectively. At 24 hours USP9X protein levels were not 
yet fully depleted (Fig. 1A). These data indicate that ReNcell VM NPs are particularly sensitive to reduced USP9X 
levels.
USP9X depletion decreases the proliferation of ReNcell VM cells but does not result in morpho-
logical changes, apoptosis or differentiation. The xCELLigence cell index, which measures electrical 
impedance, does not distinguish between effects on cell proliferation, morphology or cell death. Therefore we 
examined the effect of USP9X knock-down on these functions. No changes in ReNcell VM morphology were 
observed but a clear reduction in the cellular density of USP9X depleted ReNcell VM could be distinguished at 
72 hours after doxycycline treatment (Supplementary Fig. S1A). In addition, lower MTT levels were detected 
in USP9X depleted ReNcell VM after 48 and 72 hours doxycycline treatment consistent with decreased cell 
numbers (Supplementary Fig. S1B). Analysis of both Annexin V (Supplementary Fig. S2) and cleaved caspase 3 
(Supplementary Fig. S3A) indicated there was no increase in apoptosis, after 12 and 72 hours doxycyline treat-
ment, respectively. Immunoblot analysis failed to detect any change in the level of the astrocytic marker GFAP 
or neuronal marker βIII-tubulin, indicating that loss of USP9X did not induce the differentiation of ReNcell 
VM cells to post-mitotic cell fates (Supplementary Fig. S3B). Finally, to directly determine the effect on USP9X 
knockdown on cell proliferation an EdU pulse assay was performed to label cells undergoing DNA synthesis 
during S-phase. Significantly fewer EdU positive cells were detected in 2193 and 4774 cells treated with doxycy-
cline for 72 hours compared to those expressing the scrambled shRNA (Fig. 1C,D). These data demonstrate that 
loss of USP9X decreases the proliferation of ReNcell VM cells but does not alter their morphology, cell death or 
differentiation.
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Figure 1. USP9X depletion reduces ReNcells VM proliferation. (A) Doxycycline treatment depleted USP9X 
protein levels after 24, 36 and 72 hours in ReNcell VM cells harbouring USP9X-targeted shRNA (2913 and 4774) 
but not a nonsense shRNA (Scrambled) or non-transduced cells (Wildtype). Blot representative of six biological 
replicates. Gels were run under the same experimental conditions. USP9X and β-tubulin proteins at expected 
molecular weights. (B) Reduced Cell index of ReNcell VM cells following addition of 1 μM Doxycycline 
(0 hour). xCELLigence real-time measurement of increasing electrical impedance plotted on “Y axis” 
(“Normalised Cell Index”). Cell Index of doxycycline treated (+) ‘2193’ ReNCell VM cells differed significantly 
from non-treated after 34 hours (p < 0.05), 35 hours (p < 0.01) and 36 hours (p < 0.001). After 72 hours, the 
cell index was approximately 50% of untreated 2193 cells. For ‘4774’ cells, the cell index differed significantly at 
28 hours (p < 0.05), 29 hours (p < 0.01) and 30 hours (p < 0.001) after treatment. After 72 hrs, the reduction in 
cell index was approximately 61% that of untreated 4774 cells. Analysis was obtained by plotting t-values of the 
two way ANOVA analysis (versus time). Error bars represent standard deviation. wt: wildtype, scr: scrambled, 
+: 1 μM doxycycline treated, −: No doxycycline. Representative of two biological replicates. (C) ReNcell VM 
cells exposed to doxycycline for 72 hours were labelled with a 6 hour pulse of EdU, to mark cells undergoing 
DNA-synthesis in S-phase, before immunofluorescence staining for GFP (transduced cells) and EdU (Red). (D) 
Quantitation of cell counts revealed significantly fewer EdU-positive cells in doxycycline-treated 2193 and 4774 
cells compared to Scrambled. A minimum of 200 cells from each of two biological replicates, for each treatment, 
was counted. All data are means ± SEM. Statistical significance was assessed by one-way ANOVA, followed by 
Tukey’s post-test. **p < 0.01.
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USP9X depletion results in G0/G1 cell cycle arrest. To investigate if USP9X depletion affected ReNcell 
VM cell cycle, flow cytometric profiling of cellular DNA content was conducted. Knock-down of USP9X resulted 
in an increase in cells at the G0/G1 stage of the cell cycle 72 hours after doxycycline treatment (Fig. 2A,B). Over 
three biological replicates the average increase in cells in G0/G1 following USP9X depletion was 12.6% ± 6.3 
(p = 0.0134) for “2913” and 22.91% ± 8.9 (p = 0.0065) for “4774” cells. There was no statistically significant alter-
ation in wildtype or scrambled shRNA cells exposed to doxycycline (Fig. 2B). Removal of doxycycline from the 
culture medium resulted in restored levels of USP9X and ReNcell VM proliferation (data not shown). These data 
indicated that USP9X is required for progression of ReNcell VM cells through G0/G1 and/or progression into 
S-phase. To investigate the molecular mechanism contributing to the accumulation of cells in G0/G1 phase we 
examined, by immunoblot, the levels of various proteins facilitating the G1/S phase transition. A decrease in 
the phosphorylated form of retinoblastoma protein (pp-RbS780) was detected in USP9X depleted cells, but only 
after 72 hours of doxycycline treatment. No consistent changes in other proteins including Cyclin D1 or E2F1 
were observed at any stage of the time course (Supplementary Fig. S4). As the xCELLigence cell index of USP9X 
depleted ReNcell VM cells plateaued at 24 hours this suggested that decreases in pp-RbS780 were unlikely to be the 
mechanism initiating the G0/G1 arrest.
USP9X depletion in ReNcell VM cells reduces mTORC1 signalling. It has recently been reported 
that USP9X interacts with the mTOR signalling pathway15, a major regulator of progression through the G1 
phase of the cell cycle. mTOR exists in two complexes, mTORC1 and mTORC2, and the activity of each pathway 
is measured by the phosphorylation of their substrates, S6 and Akt, respectively15, 17–19. In the absence of growth 
factor stimulation, cells arrest in G0. However, re-addition of growth factors promptly activates mTOR signal-
ling. Therefore we examined the activation of mTOR in ReNcell VM cells, by the re-addition of EGF and FGF, 
in the presence and absence of USP9X. ReNcell VM cells were exposed to doxycycline for 72 hours for maximal 
knock-down of USP9X, and a further 24 hours in the absence of EGF and FGF to cause G0 arrest. Upon the 
reintroduction of EGF and FGF there was a rapid increase in pS6 levels, dependent on the presence of USP9X 
(Fig. 3A,E). A failure to induce pS6, in the absence of USP9X, was observed in each of six biological replicates. 
There were no obvious or consistent alterations in pAKT, total S6 (Fig. 3A) or total AKT (data not shown) protein 
levels across the biological replicates. To determine if the decreased mTORC1 signalling occurred with similar 
kinetics to the observed cell index plateauing (Fig. 1B) upon USP9X depletion, we examined pS6 protein levels 
following 24 hours doxycycline treatment. A similar decrease in pS6 levels in the absence of USP9X was detected 
at this earlier time point (Fig. 3B) suggesting this may account for the plateauing cell index detected in the xCel-
ligence assay.
Phosphorylation of S6 occurs at the end of the mTORC1-signalling cascade. We therefore examined the pro-
tein levels of upstream components of mTORC1, and mTORC2. The levels of total and p-mTOR (Fig. 3C and 
Supplementary Fig. S5A–C), phospho-p70S6 kinase (pp70S6K, data not shown) and RICTOR (Supplementary 
Fig. S5D), were not altered in the absence of USP9X following 72 hours of doxycycline treatment, however, a 
reduction in total RAPTOR levels was evident (Fig. 3D,F) and observed in three additional biological replicates 
(Figs 3F and 4F and Supplementary Fig. S6).
USP9X binds and regulates RAPTOR levels. RAPTOR is the major scaffolding protein of the mTORC1 
complex and also binds p70S6K20, 21. The level of RAPTOR protein is reportedly regulated by ubiquitylation22, 
23 raising the possibility that USP9X maintains mTORC1 signalling by opposing RAPTOR degradation in the 
ubiquitin-proteasome system. If so, the levels of substrate, RAPTOR, should correlate with those of the deubiqui-
tylating enzyme, USP9X. We’ve shown that loss of USP9X correlated with decreased levels of RAPTOR (Fig. 3D,F, 
Supplementary Fig. S6). To further investigate the relationship between these proteins, we determined if endoge-
nous Usp9x and Raptor proteins interacted by performing immunoprecipitation on lysate from the frontal cortex 
of embryonic mouse brains, which are enriched for NPs. A clear interaction between endogenous Usp9x and 
Raptor proteins was detected, as was a weaker interaction with p70S6K in E14.5 tissue (Fig. 4A). Interestingly, no 
interaction between Usp9x and mTOR was detected under these conditions. In addition, immunoprecipitation 
using anti-RAPTOR antibodies enriched for Usp9x (Fig. 4B). Therefore USP9X and RAPTOR interact in vivo. 
Next, USP9X was transiently over-expressed in HEK293 cells (due to low transfection efficiency of ReNcell VM 
cells). Increased levels of USP9X resulted in increased RAPTOR but did not alter the level of other mTORC1 
pathway components including mTOR or total S6 (Fig. 4C, Supplementary Figure S7). Over-expression of three 
USP9X mutations, which are associated with human intellectual disability but do not affect their deubiquitylating 
activity13, also increased RAPTOR levels (Fig. 4C).
The above loss- and gain-of-function approaches, in human ReNcell VM cells and HEK293T cells, respec-
tively, identified a direct correlation between USP9X and RAPTOR protein levels but they do not indicate if 
USP9X’s deubiquitylating activity is required. Recently a small compound, WP1130, has been identified which 
inhibits USP9X DUB activity, but does not affect USP9X protein level24. In addition, WP1130 rapidly inhibits 
USP9X within hours, compared with days for RNA knock-down approaches and thereby circumvents possi-
ble induction of compensatory DUB expression24. The addition of WP1130 to proliferating ReNcell VM cells 
under normal culture conditions, in the presence of EGF and FGF, resulted in a rapid (2 hours) decrease in 
RAPTOR protein levels but had no effect on pp70S6K (Fig. 4D and Supplementary Fig. S7). As reported by oth-
ers, WP1130 did not affect the level of USP9X protein, but did deplete another USP9X substrate, MCL125 after 
4 hours. Therefore, inhibition of USP9X’s deubiquitylating activity leads to a rapid decrease in RAPTOR protein 
in ReNcell VM cells.
USP9X opposes proteasomal degradation of RAPTOR. The above data are consistent with USP9X 
opposing the degradation of RAPTOR in the ubiquitin-proteasome system. To directly examine this, we 
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Figure 2. Loss of USP9X results in ReNcell VM cell accumulation in the G0/G1 phase of cell cycle. (A) Flow 
cytometric analysis of ReNcell VM cells after 72 hours of doxycycline treatment. Representative of three 
biological replicates. (B) Quantitation of percentage of cells in each cell cycle phase from three biological 
replicates. All data are shown as the means ± SEM. Statistical significance was assessed by the unpaired Student’s 
t test. *p < 0.05.
www.nature.com/scientificreports/
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Figure 3. mTORC1 activity and RAPTOR levels in ReNcell VM cells are dependent on USP9X. (A) 
Immunoblot analysis of growth factor induction of mTORC1 and mTORC2 pathways in absence of USP9X. 
USP9X was depleted from 2193 and 4774 cells by 72 hours exposure to doxycycline before growth factors (EGF/
FGF) were removed from ReNcell VM medium 24 hours prior to protein collection (0 minutes) and then 5 
and 15 minutes after re-addition of EGF/FGF. Both pS6 and pAkt levels increased upon exposure to EGF/FGF 
(compare 0 to 5 and 15 min) indicating both mTORC1 and mTORC2 pathway activation, respectively. However, 
the extent of induction for pS6 was markedly reduced in the absence of USP9X (compare plus and minus Dox at 
5 and 15 mins in 2193 and 4774). Total S6 and Total AKT were not affected by USP9X depletion. Representative 
of three biological repeats. (B) Diminished mTORC1 activation in ReNcell VM cells, as determined by pS6 
levels, was evident after only 24 hours doxycycline treatment, consistent with the xCELLigence data. (C) 
Phospho and Total mTOR levels were unaffected by the absence of USP9X. Representative of two biological 
replicates. Full length blots presented in Supplementary Fig. S8. (D) RAPTOR protein levels were decreased 
in ReNcell VM cells with depleted USP9X (2193 and 4774 plus doxycycline) Representative of three biological 
replicates. (E) Densitometric quantitation, of immunoblots from two biological replicates, of initial pS6 
induction compared to total S6 levels 5 mins after addition of EGF/FGF in the absence or presence of 
doxycycline. The treatment of cells with doxycycline significantly attenuated the level of pS6 in 2193 and 4774 
cells only. (F) Densitometric quantitation of immunoblots, from three biological replicates, of RAPTOR protein, 
relative to β-tubulin control, at time 0 hour in the absence or presence of doxycycline. The treatment of cells 
with doxycycline significantly attenuated the level of RAPTOR in 2193 and 4774 cells only. All data are shown as 
the means ± SEM. Statistical significance was assessed by the unpaired Student’s t test. *p < 0.05.
www.nature.com/scientificreports/
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Figure 4. USP9X regulates RAPTOR levels and opposes its proteasomal degradation in neural progenitors. 
(A,B) Co-immunoprecipitation of endogenous Usp9x and Raptor from E14.5 mouse frontal cortex. (A) Anti-
Usp9x antibodies precipitated Raptor protein. An interaction with pp70S6 kinase was also detected. (B) Anti-
Raptor antibodies precipitated Usp9x protein. (C) USP9X over-expression increased RAPTOR protein levels. 
Proliferating HEK293T cells were transiently transfected with empty vector, full length USP9X (WT) or one 
of three USP9X variants, which do not affect enzymatic activity but are associated with human intellectual 
disability. Cell lysates were collected 24 hours later. Immunoblot analysis identified increased RAPTOR protein 
but mTOR and total S6 levels were unaffected. (D) Chemical inhibition of USP9X deubiquitylating activity 
leads to a rapid depletion of RAPTOR protein in neural progenitors. ReNcell VM cells were treated with 5 μM 
WP1130 and analysed by immunoblot. WP1130 does not deplete USP9X protein levels over 4 hours but results 
in almost complete loss of RAPTOR by 2 hours. pp70S6 kinase levels were not affected. Levels of another USP9X 
substrate MCL1 were depleted after 4 hours. (E) RAPTOR protein levels are regulated by proteasomal inhibition 
(epoxomicin) and inactivation of USP9X deubiquiytlating activity (WP1130) in ReNcell VM cells. Proteasomal 
inhibition following 4 hours exposure to 25 nM epoxomicin resulted in increased RAPTOR levels. Inhibition 
of USP9X DUB activity with 5 μM WP1130 for 4 hours resulted in decreased RAPTOR. Treatment of wild-
type ReNcell VM cells for 4 hours with WP1130 followed by 4 hours of epoxomicin resulted in intermediate 
levels of RAPTOR. DMSO was used as the vehicle control for each experiment. Final concentrations of DMSO 
were – 0.0025% for epoxomicin; 0.00005% for WP1130; 0.00255% for WP1130 + Epoxomicin. (F) Epoxomicin 
treatment of 2193 and 4774 ReNcell VM cells resulted in increased RAPTOR protein levels. The addition of 
doxycycline (+DOX) resulted in intermediate levels of RAPTOR. Representative of two biological replicates.
www.nature.com/scientificreports/
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measured RAPTOR levels in ReNcell VM cells treated with the proteasome inhibitor, epoxomicin26. Epoxomicin 
treatment for 4 hours increased RAPTOR levels (Fig. 4E lane 2) suggesting it is subject to proteasomal degra-
dation in ReNcell VM cells. As shown previously, inhibition of USP9X deubiquitylating activity by WP1130 
resulted in depleted RAPTOR levels (Fig. 4E lane 4). The combination of epoxomicin and WP1130 resulted in 
intermediate levels of Raptor protein compared with epoxomicin or WP1130 alone (Fig. 4E, compare lane 6 with 
2 and 4). These data are consistent with USP9X’s deubiquityling activity opposing degradation of RAPTOR by the 
proteasome. However, as WP1130 activity inhibits deubiquitylating enzymes other than USP9X27 proteasomal 
inhibition experiments were repeated in the 2193 and 4774 ReNcell VM lines to validate a specific role for USP9X 
in the inhibition of RAPTOR degradation. As for WP1130, doxycycline knockdown of USP9X produced similar 
results (Fig. 4F, Supplementary Fig. S8). Furthermore, qRT-PCR analysis indicated that loss of USP9X did not 
affect Raptor mRNA levels (Supplementary Fig. S9) consistent with post-translational regulation.
USP9X null neurospheres have reduced neural progenitor proliferation but not stem cell 
self-renewal. The mTORC1 pathway is well known to regulate murine NP proliferation. Inactivation of 
mTORC1 signalling in NPs in vivo, by conditional Nestin-cre mediated deletion of the Raptor gene in mouse 
brains, resulted in reduced NP proliferation. When mTORC1 signalling is inhibited in NSC/NPs cultured ex-vivo 
as neurospheres, the reduced NP proliferation manifested as a reduction of neurosphere size8. We therefore per-
formed neurosphering assays on Usp9x−/Y NSC/NPs derived from late embryonic stage mouse brains following 
Nestin-cre deletion of Usp9x12. Neurospheres contain a heterogeneous population of NSC, NP and differentiated 
neural cells28. Upon single cell dissociation and re-culture at very low density, to exclude cell aggregation, only cells 
with stem cell-like properties reform neurospheres29–32. These spherogenic neural stem cells typically represent 
only ~1–5% of the cells derived from neurospheres28, 30, 32. In contrast NPs have very limited capacity to reform 
spheres over multiple passages. We applied the well-established serial passage sphere-forming assay to identify the 
effect, if any, of Usp9x loss on the long-term self-renewal of the spehrogenic NSC population. In this assay, a set 
number of single NPs are plated at very low density following each passage (1 × 104 cells/ml) and the number of 
spheres that form in those cultures then counted. Over several passages, Usp9x−/Y cultures consistently contained 
significantly more neurosphere forming cells (2. 6% compared to 1.7%; p < 0.05; Fig. 5B). Next we asked if the loss 
of Usp9x had any effect on the multipotency of the NSC/NPs (Fig. 5C,D). As each sphere is derived from a single 
cell, the cell types a sphere can produce reflects the multipotency of the original sphere-forming cell28, 32. Spheres 
were plated at very low density and allowed to differentiate before identifying the three basic neural lineages that 
are produced from embryonic NSCs, namely, neurons, astrocytes and oligodendrocytes (Fig. 5C). We scored indi-
vidual spheres for the presence of all three, two or one lineages as tri-, bi and mono-potent respectively. The major-
ity of spheres (70–73%) were tri-potent, and there were no significant differences between Usp9x+/Y and Usp9x−/Y 
cultures, suggesting loss of Usp9x had no effect on the multipotency of the sphere-forming stem cells (Fig. 5D). 
Given the increase in the number of spheres in Usp9x−/Y cultures, we asked if this resulted into an increase in the 
absolute number of cells that were produced during culture, however, both Usp9x+/Y and Usp9x−/Y cultures pro-
duced equivalent cell numbers across several passages (Fig. 5E). This finding had two implication; firstly that the 
increased percentage of sphere forming cells in Usp9x−/Y cultures translated into increases in the absolute number 
of sphere forming cells in the cultures (Fig. 5F); and secondly, that individual neurospheres in Usp9x−/Y cultures 
must contain fewer cells. Indeed, on average, neurospheres in Usp9x−/Y cultures displayed modest but significant 
reductions in the number of cells per sphere (30% reduction; ~95 compared to ~66 cells/sphere), which was also 
reflected in reductions in the average sphere diameter (24% reduction; ~79 compared to ~60 μm/sphere) at the 
time of passaging (Fig. 5A,G,H). Therefore, while loss of Usp9x promoted the self-renewal and expansion of the 
sphere-forming population, the bulk growth of the sphere after formation was compromised. To investigate if this 
loss of bulk growth could be attributed to altered differentiation behaviour, we used immunofluorescence to reveal 
the expression of cell-type specific marker proteins to identifying cell types present in the spheres. As it is techni-
cally difficult to resolve in the 3D environment of a neurosphere, we dissociated the neurosphere cultures into sin-
gle cells and plated them onto coverslips. Following attachment overnight and 24 hours growth, cells were fixed and 
stained for marker proteins of NPs (Sox2), neurons (βIII-tubulin) and astrocytes (GFAP) and nuclei counterstained 
with DAPI (Fig. 5I). Using this labelling regime, greater than 99% of all cells were labelled (data not shown). At this 
time, there was already a 51% reduction in total cell numbers (Fig. 5J). This reduction was solely due to a loss of 
Sox2-positive NPs (67% decrease) with the numbers of astrocytes and neurons being equivalent. To directly test if 
the absence of Usp9x affected NP proliferation, neurospheres were exposed to a 6 hour EdU pulse followed by cell 
counts (Fig. 5K,L) or flow cytometry (Supplementary Fig. S9). As was observed for ReNcell VM cells, significantly 
fewer Sox2-positive NPs were proliferating (EdU-positive) in the Usp9x-deleted neurospheres.
In aggregate these data strongly suggest the absence of Usp9x in neurospheres promotes the self-renewal of a 
rare population of sphere-forming cells that displays the properties consistent with that of NSCs, whilst simulta-
neously inhibiting the proliferative capacity of the bulk transiently amplifying NP population. This phenotype, of 
smaller neuropsheres and reduced NP proliferation but not their self-renewal, is shared with the central features 
of both Raptor null or rapamycin treated neurospheres8 and together suggests that Usp9x may also be required to 
regulate mTORC1 function in NPs in neurospheres.
USP9X regulates mTORC1 activity in vivo. Next the functional consequence of Usp9x depletion on 
Raptor levels and mTORC1 signalling in vivo during embryonic brain development was determined by immu-
noblot. Significantly lower levels of pS6 protein were detected in Usp9x−/Y brains at E12.5, however in contrast to 
cultured human ReNcell VM and HEK293 cells no effect was observed on Raptor (Fig. 6C–E). Similar analysis 
on neurospheres derived from E18.5 brains confirmed a dependence of pS6 levels on Usp9x, but not Raptor 
(Fig. 6F–H). These data support a role for USP9X in the maintenance of mTORC1 pathway signalling in both 
mouse and human NPs.
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Figure 5. Loss of Usp9x promotes stem-cell self-renewal and loss of bulk NP proliferation. Neurosphere 
cultures were derived from the cortices of E18.5 Usp9x+/Y (n = 4) and Usp9x−/Y (n = 5) mice. (A) Representative 
phase contrast images Usp9x+/Y and Usp9x−/Y neurospheres. (B) Usp9x−/Y cultures contain a higher percentage 
of sphere-forming cells. The average percentage of cells from dissociated neurospheres, that re-form spheres 
at very low density, was derived over several passages. (C,D) Loss of Usp9x does not affect the multipotency 
of sphere-forming cells. Whole neurospheres (passage 2, n = 3 for Usp9x−/Y and Usp9x−/Y) were plated at 
low density and outgrowths stained and scored after 6 days. (C) Representative image of cultures labelled 
for cell type marker proteins GFAP: astrocytes; βIII-tubulin: neurons and CNPase: oliogodendrocytes. (D) 
The percentage of neurosphere outgrowths displaying tri - bi and mono-potency scored and compared by 
Student t-test (not statistically different). (E) Usp9x+/Y and Usp9x−/Y cultures contain equivalent number of 
cells at each passage. (F) Usp9x−/y cultures contain increased numbers of sphere forming cells. Total sphere-
forming cells calculated across several passages. (G,H) Usp9x−/Y neurospheres are smaller. Mean diameter 
and number of cells per neurosphere at each passage. (I,J) Loss of Usp9x decreases NP number. Neurosphere 
cultures (passage 2, n = 3 for Usp9x−/Y and Usp9x−/Y) were dissociated and plated at very low density onto poly-
l-lysine coated plates in media containing EGF and cultures fixed 24 hours later. (I) Representative image of 
immunofluorescently stained cultures; cells labelled for cell markers; Sox2: NP; GFAP: astrocytes; βIII-tubulin: 
neurons. Cell nuclei counterstained with DAPI. (J) Cell counts used to quantify numbers of cell types present in 
cultures. (K,L) Loss of Usp9x inhibits NP cell proliferation. (K) Representative images of neurospheres allowed 
to attach for 2 hours followed by a 6 hour EdU pulse and immunostained for the NP marker Sox2 (Green) 
and EdU (Red). (L) Lower percentage of Usp9x−/Y NPs (Sox2-positive) were labelled with EdU indicating 
diminished NP proliferation. Scale bar = 50μm. All data are shown as the means ± SEM. Statistical significance 
was assessed by the unpaired Student’s t test.*p < 0.05; ***p < 0.001.
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Figure 6. USP9X binds RAPTOR and regulates mTORC1 activity in vivo. (A) Immunoblot analysis of 
Usp9x, Raptor and pS6 protein from E12.5 Usp9x+/Y (n = 7) and Usp9x−/Y (n = 4) mouse forebrains. (B,C) 
Densitometric analysis of (A) revealed no change in Raptor (B) but significantly lower levels of pS6 (C) protein 
levels in Usp9x−/y brains. (D) Immunoblot analysis of Usp9x, Raptor and pS6 protein from E18.5 derived 
neurospheres (3 Usp9x+/Y versus 4 Usp9x−/Y). No difference was observed in Raptor protein levels (E) but pS6 
levels (F) were significantly decreased in Usp9x−/Y neurospheres. All data are shown as the means ± SEM. 
Statistical significance was assessed by the unpaired Student’s t test. *p < 0.05; **p < 0.01.
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Discussion
USP9X is highly expressed in, and regulates the function of, NPs both in vivo and in vitro11, 12, 33. Previously, 
increased expression of Usp9x was shown to regulate NP self-renewal by promoting apical-basal cell polarity and 
altering the architecture of NP cultures derived from mouse embryonic stem cells11. Here we show USP9X is also 
required to maintain proliferation of the human NP line ReNcell VM, in a cell autonomous manner, and this is 
probably mediated via facilitating mTORC1 pathway signalling.
Inducible knock-down of USP9X demonstrated that ReNcell VM cells are exceptionally sensitive to USP9X 
depletion. Within 24 hours of initiating USP9X knock-down, proliferation of the ReNcell VM cells halted (Fig. 1) 
despite the presence of mitogenic quantities of EGF and FGF. Considering that USP9X protein levels were not 
completely depleted at this time (in some experiments USP9X was only 50% depleted) and, that ReNcell VM 
have a cell cycle time of approximately 30 hours, this indicates that even partial depletion of USP9X results in 
a rapid and comprehensive arrest of proliferation. Although apoptosis can quickly alter cell numbers, and the 
anti-apoptopic protein MCL1 is a USP9X substrate in some cellular contexts25, no alterations in Annexin V 
or cleaved caspase 3 levels were detected, indicating no increase in apoptosis (Supplementary Figs S2 and S3). 
Nor did USP9X depletion promote the differentiation of ReNcells VM to post-mitotic neuronal or glial lineages 
(Supplementary Fig. S3). Instead the NPs accumulated in the G0/G1 phase of the cell cycle (Fig. 2). This rapid 
response was not due to alterations in G1/S check-point proteins, although a delayed decrease in pRb levels was 
observed.
The mTOR pathway regulates progression through the G0/G1 stage of the cell cycle2 and Usp9x influences 
mTORC1 and mTORC2 pathway activity in the C2C12 mouse myoblast cell line15. Here we show that USP9X is 
required for mTORC1, but not mTORC2, activity in ReNcell VM human NPs. The depletion of USP9X levels, loss 
of mTORC1 signalling, as indicated by failure to induce p-S6, and ReNcell VM cell-cycle arrest, all occurred with 
very similar kinetics strongly suggesting these NPs rely on USP9X-dependent mTORC1 activity for proliferation.
Post-translational modification of mTOR proteins, including by ubiquitylation, allow the mTOR pathway to 
respond rapidly to changing extra-cellular signals. Both p-mTOR and RAPTOR are targeted for proteasomal deg-
radation by poly-ubiquitylation23, 34. Here we present several lines of evidence identifying the canonical mTORC1 
scaffold protein, RAPTOR, as a probable USP9X substrate in NP/NSCs. Firstly, we show that endogenous USP9X 
and RAPTOR proteins co-immunoprecipitate from mouse embryonic brain tissue enriched for NPs (Fig. 6A,B). 
USP9X did not interact with mTOR under the same conditions. The much weaker interaction detected between 
USP9X and pp70S6K (Fig. 6A) may be direct or indirect via RAPTOR, which binds pp70S6K to recruit it to the 
mTORC1 complex21. The absence of any alteration in pp70S6K levels following the inhibition of USP9X activity 
(Fig. 4B), suggests USP9X does not directly regulate phospho-p70S6K.
Second, inducible USP9X-specific shRNA-mediated knock-down (Fig. 3C,E, Supplementary Fig. S6), and 
transient over-expression of full length USP9X (Fig. 4A) resulted in a concomitant decrease and increase in 
RAPTOR protein, respectively. Use of the chemical WP1130, which rapidly inhibits USP9X’s deubiquitlyating 
activity but does not deplete USP9X protein levels, confirmed a clear and rapid loss of RAPTOR (Fig. 4C). The 
near complete depletion of RAPTOR protein within 2 hours strongly suggests that USP9X regulation occurs at the 
post-translational level. This is supported by the observation that the loss of MCL1, a bona fide USP9X substrate, 
occurred only after 4 hours in the same experiment (Fig. 4C). However, as WP1130 inhibition is not restricted to 
USP9X, we cannot rule out the possibility that other DUBs, in addition to USP9X, might also regulate RAPTOR 
stability. To address this we analysed ReNcell VM cells with inducible USP9X-specific shRNA-mediated knock-
down and these produced similar results to WP1130 (Fig. 4D) suggesting USP9X plays a significant, if not exclu-
sive, role in maintaining RAPTOR levels in NPs.
An obvious hypothesis is that USP9X’s deubiquitylating activity opposes RAPTOR’s degradation at the protea-
some. Data presented (Fig. 4C,D) confirmed that inhibition of the proteasome increased RAPTOR protein levels 
in ReNcell VM cells as observed in HEK293T cells23, and that inhibiting the proteasome, in the absence of USP9X 
activity partially rescued RAPTOR levels. USP9X is the first deubiquitylating enzyme shown to stabilize, compo-
nents of the mTOR pathway namely, RAPTOR. Although another deubiquitylating enzyme, UCH-L1 has been 
shown to impact upon mTORC1 signalling it does so indirectly by affecting assembly of the mTORC1 complex23. 
Unlike USP9X, UCH-L1 has no effect on the protein levels of mTOR complex components including RAPTOR.
USP9X’s regulation of mTOR signalling appears to be cell context specific. Recently it was shown in C2C12 
muscle myoblasts that epitope-tagged USP9X weakly associated with mTOR and both RAPTOR and RICTOR 
in HEK293T cells and its depletion in C2C12 myoblasts accelerated their differentiation to myotubes15. In con-
trast to our results in NPs, Usp9x depletion from C2C12 cells led to increased mTORC1 activity, in response to 
growth factor stimulation. Interestingly, while Usp9x depletion in C2C12 cells altered the downstream mTORC1 
and mTORC2 effectors, pS6 and pAKT, respectively, no alteration in the levels of the upstream proteins mTOR 
or RAPTOR, were detected. Therefore in C2C12 myoblasts, the regulation of mTOR signalling by Usp9x may be 
indirect. Cell context specific roles of USP9X have also been observed in other systems25, 35, 36. Although Usp9x 
has been identified as a potential regulator of stem cell function37, decreasing Usp9x levels does not overtly dimin-
ish the proliferation of other progenitor/stem cells including, embryonic stem cells38, T-cell progenitors39 or pan-
creatic progenitors36. In contrast, the data presented here indicates that both cultured human NPs and, those in 
mouse neurospheres, are particularly sensitive to USP9X levels.
mTOR signalling is a major regulator of NP function in both development and disease4. Our data establish 
that USP9X facilitates mTORC1 signalling in NPs in both cultured human NPs, neurospheres and the developing 
mouse brain. Our data also reveals the phenotype of Usp9x null neurospheres is very similar to that reported 
for rapamycin treated and Raptor depleted neurospheres8 and is therefore consistent with Usp9x stabilisation of 
mTORC1 signalling in mouse NPs as well. Loss of either Usp9x or Raptor resulted in smaller neurospheres but 
did not affect their capacity for serial passage indicating they affected proliferation of NPs without inhibiting 
the self-renewal capacity of the sphere-initiating NSC. Likewise rapamycin treatment of neurosphere cultures 
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resulted in reduced NP proliferation (and reduced neurosphere size) without affecting the stem cell state9, and 
rapamycin delivery to the adult sub-ventricular zone neurogenic niche specifically depleted the transiently ampli-
fying NPs but not the stem cell population40. These data are consistent with retention of transiently amplifying 
NPs in the G0 stage of the cell cycle, a phenomenon reported for adult neural stem cells exposed to rapamycin40. 
However, we did not detect a significant decrease in Raptor protein in Usp9x-null neurospheres, nor embryonic 
brain as assessed by immunoblot (Fig. 6C,D,F,G) like that observed in the human ReNcell VM neural progenitors. 
This may be due to the presence of a compensatory mechanism in the increasingly complex cellular composition 
of embryonic neural development over time or, the non-synchronised nature of cycling NPs or the presence of 
mitogens, as initial experiments on asynchronously growing ReNcell VM cells in the presence of mitogens also 
failed to detect significantly altered pS6 levels in, at least by immunoblot (data not shown). It is also possible that 
USP9X interacts with different mTORC1 components in human and mouse neural progenitors.
Finally, we observed that the loss of Usp9x resulted in more neurosphere-initiating stem cells at each passage, 
despite fewer proliferating NPs. This suggests that mTORC1 is not the only pathway regulated by USP9X in NPs, 
as inhibition of RAPTOR function in neurospheres did not produce a similar increase in sphere-forming cells. 
In addition, in embryonic stem cell-derived NPs in–vitro, a moderate increase in Usp9x levels promotes NP 
self-renewal11. Indeed USP9X regulates components of multiple pathways important to NP fate including the 
Notch, Wnt and TGF-β pathway10 and the final outcome is very much dependent on the type of NP. Consistent 
with a context-specific role for USP9X in the regulation of NP self-renewal we recently reported that loss of Usp9x 
has a differential effect on quiescent versus proliferating NSCs in the postnatal mouse hippocampal subgranular 
zone33. It is possible that Usp9x promotes the proliferation of intermediate progenitor cells at the expense of 
NSC self-renewal in the postnatal hippocampus. The differential dependence of NPs and sphere-forming NSCs 
on Usp9x may reflect a similar molecular mechanism. As Usp9x regulates brain development in mice12 and is 
associated with several human neurodevelopmental disorders13, 41 the precise role of Usp9x in NPs and stem cells 
warrants further investigation.
Materials and Methods
Generation of inducible Usp9x knock-down ReNcells VM lines. The human neural stem cell line 
ReNcells VM was obtained from Millipore (Darmstadt, Germany) and maintained as described42. To generate 
ReNcells VM with doxycycline-inducible knock-down of USP9X, cells were transduced with a lentiviral vector43 
containing either a “scrambled” shRNA sequence: 5′ACTACCGTTGTTATAGGTGTTCAAGAGACACCTA 
TAACAACGGTAGT3′ with no homology to any known gene, or shRNA targeting two independent USP9X 
sequences “2193” 5′GCTTGATCCTTCCCTGTTAAC3′ (the first base pair is 2193 in the human USP9X 
sequence) or “4774” 5′GCCATAGAAGGCACAGGTAGT3′. Successfully transduced pools of ReNcells VM were 
isolated by FACS based on constitutive EGFP expression43. These transduced pools were used in subsequent 
experiments. Induction of shRNA expression was achieved by supplementing the media with 1 μM doxycycline.
Functional analysis of ReNcells VM. xCELLigence Assays. The xCELLigence system for real-time cell 
viability monitoring was used as described44. Briefly, ReNcell VM cells were plated at 5 × 103 per well and 1 μM 
doxycycline added the following day. The plate was analysed by xCELLigence (Roche, Basel, Switzerland) in real 
time over 5 days of doxycycline treatment.
MTS Assay. The MTS assays were performed according to the manufacturer’s instructions (Promega, AUS).
Annexin V Apoptosis Assay. Cells were seeded at 2 × 105 cell/ml and treated with 1 μM doxycycline 12 hours 
later. After 12 hours treatment, cells were harvested by centrifugation at room temperature for 5 mins at 0.4 rcf and 
subjected to Annexin V assay as per the manufacturer’s instructions (Trevigen, Gaithersberg, USA).
Cell Cycle Analysis. Cells were seeded at 2 × 105 cell/ml and treated with 1 μM doxycycline 12 hours later. Cells 
were in log phase at time of harvest. Cells were washed with HBSS and centrifuged for 5 mins at 0.3 rcf before 
suspension in 1 ml HBSS and fixation at 4 °C for 1 hour in 100% cold ethanol. Cells were stained with Propidium 
Iodide staining solution (3.8 mM Sodium Citrate, 50 μg/ml PI in DPBS) and 50 μl of RNase A stock solution 
(10 μg/ml RNase A in DPBS) was added. Tubes were stored at 4 °C until Flow cytometry analysis using a Becton 
Dickinson FACSAria.
Molecular analyses. Immunoblotting. Cells were lysed with RIPA lysis buffer (150 mM NaCl, 1.0% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris, pH 8.0) supplemented with 
100 μl/mL protease inhibitor. Cell lysate was then processed for immunoblotting and visualised with ECL sub-
strate as described12. The following antibodies have been used: Primary Antibodies: Cell Signalling Technologies 
(Danvers, MA): Rabbit-Cyclin D (1/1000), Mouse- Cyclin E (HE12) (1/1000), Mouse- Cyclin A (BF683) (1/2000), 
Rabbit- Caspase-3 (1/1000), Rabbit Cleaved Caspase-3 (Asp175) (1/1000), Rabbit p-S6S235/236 (1/800), Rabbit 
Total S6 (1/2000), Mouse IgG1 mTOR (1/1000), Rabbit p-mTORS2448 (1/800), Rabbit E2F1 (1/1000), Rabbit 
pp-RbS780 (1/1000), Rabbit Rb (1/2000), Rabbit Rictor (1/800), Rabbit Raptor (1/800), Rabbit p-AktS473 
(1/1000), Rabbit t-Akt (1/2000), Rabbit p-p70S6K (1/500), Rabbit β-Tubulin (1/2000). Santa Cruz (Dallas, TX): 
Rabbit-poly MCL1 (1/500). Purified Rabbit N-terminal45 (1/2000). Bethyl Labs (Montgomery, TX): Rabbit USP9x 
C terminal (1/2000) Sigma Aldrich (St Louis, MO): Mouse β-Tubulin (1/2000), Trevigen (Gaithersberg, USA): 
Rabbit GAPDH (1/2000). Secondary Antibodies: Life Technologies (Mulgrave, AUS): Rabbit HRP (1/5000), 
Mouse HRP (1/5000). Millipore (Darmstadt, Germany): Rabbit HRP (1/5000), Mouse HRP (1/5000).
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Immunoprecipitation. Protein lysate was isolated from the frontal cortex of mid-gestation embryonic mouse 
brain to enrich for neural progenitors. The isolated tissues were lysed by sonication in the presence of the IP 
lysis buffer – 20 mM HEPES pH 7.8, 400 mM KCl, 5 mM EDTA, 0.4% NP40, 10% glycerol, 1 mM DTT, protease 
and phosphatase inhibitor cocktails (Cell Signalling, Danvers MA). Immunoprecipitation was conducted using 
Pierce co-immunoprecipitation kit (Thermo Scientific, Rockford, IL) according to manufacturer’s instructions. 
Immunoprecipitated proteins and total protein extracts were then subjected to immunoblot analysis.
Over-expression of USP9X. Transient expression of wild-type USP9X, and variant forms associated with intellec-
tual disability, in HEK293T cells was as previously described13. Briefly, cells were transfected using Lipofectamine 
2000 reagent as per manufactures instructions (Life Technologies). Cell lysates were collected after 24 hours and 
subjected to immunoblot analysis.
Neurosphere Culture. Isolation and culture of NPs from the E18 cortex was as previously described28, 46. All 
neurosphere-based assays were conducted in at least biological triplicate, with each replicate representing a neu-
rosphere culture derived from individual Usp9x+/Y or Usp9x−/Y embryos. Averages of the replicates results are 
reported. Sphere forming assays were initiated by dissociating neurospheres and isolating single cells by passing 
dissociated cells through a 0.75 µm cell filter (BD Biosciences, San Jose, CA). Single cells were replated at very 
low density (1 × 104 cells/mL) and cultured for 6 days. The number of spheres was calculated, and subsequently 
dissociated again to generate single cells for sphere forming assays. Number of cells per sphere was derived using 
total cell counts and total sphere number counts at each passage. At least 100 spheres were imaged per replicate 
and analysed using ImageJ to determine average sphere diameters. For the identification of cell types, disso-
ciated single cells from neurospheres were plated onto poly-l-lysine (Sigma, St Louis, MO) coated coverslips 
(Menzel-glasser, Thermo Fisher Scientific) at 1 × 104/cm2 in the presence of EGF and cultured for 24 hours at 
which point cells were fixed for immunofluorescent staining. The number of neuronal + astrocytes + progenitor 
cells was counted. Oligodendrocyte differentiation was negligible (<1%) and not included. At least 200 cells were 
counted per replicate (total n: Usp9x+/Y = 1299; Usp9x−/Y = 756). For analysis of multipotency, single cells derived 
from neurosphere dissociation and filtration were plated at very low density. Following 6 days culture, whole neu-
rospheres were plated onto poly-l-lysine coated coverslips at low density (30 spheres/35 mm well) and cultured for 
a further 6 days. Neurosphere outgrowths were fixed and immunofluorescently stained for the presence of termi-
nally differentiated cells namely neurons, astrocytes and oligodendrocytes. Neurosphere outgrowths were scored 
as Uni-, bi and tri-potent based on the presence of 1, 2 or all three cell types in the outgrowths, respectively. At 
least 20 outgrowths were scored per replicate (total n: Usp9x+/Y = 81; Usp9x−/Y = 68). All data points represent the 
average of replicate means and error bars represent standard deviation of replicate means. Statistical significance 
derived using Student’s 2-tailed t-test assuming equal variance and set to p < 0.05.
Immunofluorescence. Cultured cells were fixed with 4% PFA for 15 minutes at room temperature (RT) and 
block-permeablised using PBST-10% Normal Donkey Serum (NDS) for 1 hour at RT. Primary and second-
ary antibodies were incubated in 3%NDS overnight (O/N) at 4 °C and 1 hour at RT respectively at the follow-
ing dilutions; mouse anti-CNPAse, (1:2000; Chemicon, Germany), rabbit anti-GFAP, goat anti-GFAP, mouse 
anti-βIII-tubulin, rabbit anti-βIII-tubulin (all at 1:300; Sigma-Aldrich), rabbit anti-Pax6 (1:200; Chemicon, 
Germany), donkey anti-sheep Alexafluor555, donkey anti-rabbit Alexafluor488/555/647 and donkey anti-mouse 
Alexafluor488/555/647 (all 1:1000; Invitrogen), donkey anti-chickenCy3 (Jackson Laboratories, Bar Harbour, 
ME). Cells were counterstained with DAPI and mounted with Slow-fade mounting media (Invitrogen). 
Non-specific staining was controlled by using secondary-only controls. Fluorescence was viewed using the 
Axioplan2 microscope (Carl Zeiss, Jena, Germany) fitted with an HBO 100 lamp (Carl Zeiss, Jena, Germany). 
Images were captured using an Axiocam Mrm camera and Axio Vs40 v4.5.0.0 software (Axiovision, Carl Zeiss, 
Jena, Germany).
Animal Use. This study was performed with the approval of both, the Griffith University Animal Ethics 
Committee under the guidelines of the National Health and Medical Research Council of Australia and the 
Australian Commonwealth Office of the Gene Technology Regulator as well as under regulations of the South 
Australian Animal Welfare Act 1986, and in strict accordance with the Australian Code of Practice for the Care 
of Animals for Scientific Purposes, 2004. The study was approved by the Women’s and Children’s Health Network 
(WCHN) Animal Ethics Committee (Approval Number: 750/06/2011 and 888/06/13). All experiments were car-
ried out in accordance with the approved guidelines.
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